for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ACADIA Pharmaceuticals Inc.

ACAD.OQ

Latest Trade

40.74USD

Change

-0.00(-0.00%)

Volume

1,771,080

Today's Range

40.60

 - 

42.05

52 Week Range

14.01

 - 

44.84

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
40.74
Open
41.61
Volume
1,771,080
3M AVG Volume
43.17
Today's High
42.05
Today's Low
40.60
52 Week High
44.84
52 Week Low
14.01
Shares Out (MIL)
150.70
Market Cap (MIL)
6,139.69
Forward P/E
-22.82
Dividend (Yield %)
--

Next Event

ACADIA Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Acadia Pharmaceuticals Prices Underwritten Public Offering Of 6.25 Mln Shares At $40/Shr

Acadia Pharmaceuticals - Intends To Offer And Sell $250 Million Of Its Common Stock

Acadia Pharmaceuticals Announces Pivotal Phase 3 Harmony Trial Stopped Early For Positive Efficacy As Pimavanserin Meets The Primary Endpoint In Patients With Dementia-Related Psychosis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

Industry

Biotechnology & Drugs

Contact Info

3611 Valley Centre Dr Ste 300

+1.858.5582871

http://www.acadia-pharm.com/

Executive Leadership

Stephen R. Biggar

Independent Chairman of the Board

Srdjan Stankovic

President

Stephen R. Davis

Director and Chief Executive Officer

Elena H. Ridloff

Executive Vice President, Chief Financial Officer

Austin D. Kim

Executive Vice President, General Counsel, and Secretary

Key Stats

1.92 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.1K

2018

0.2K

2019(E)

0.3K
EPS (USD)

2016

-2.340

2017

-2.360

2018

-1.940

2019(E)

-1.785
Price To Earnings (TTM)
--
Price To Sales (TTM)
23.25
Price To Book (MRQ)
15.13
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-80.83
Return on Equity (TTM)
-69.05

Latest News

Acadia's schizophrenia treatment misses late-stage main goal; shares fall 16%

Acadia Pharmaceuticals Inc said on Monday its add-on treatment for schizophrenia failed to meet the main goal in a late-stage study.

Acadia's schizophrenia treatment fails to meet main goal of late-stage study

Acadia Pharmaceuticals Inc said on Monday its add-on treatment for schizophrenia failed to meet the main goal in a late-stage study.

BRIEF-Acadia Pharmaceuticals Q1 Loss Per Share $0.44

* ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Acadia Pharmaceuticals Says CEO Stephen Davis's FY 2017 Total Compensation Was $15.2 Mln

* ACADIA PHARMACEUTICALS SAYS CEO STEPHEN DAVIS'S FY 2017 TOTAL COMPENSATION WAS $15.2 MILLION, INCLUDING $13.9 MILLION IN OPTION AWARDS - SEC FILING Source : https://bit.ly/2ra1j3J Further company coverage: (Reuters.Briefs@thomsonreuters.com)

FDA says reviewing Acadia's Parkinson's medication, shares fall

The U.S. Food and Drug Administration said on Wednesday it was reviewing Acadia Pharmaceuticals' Parkinson's medication, the only approved drug used to treat hallucinations and delusions associated with the disease.

BRIEF-Acadia Pharma Q4 Loss Per Share $0.55

* ACADIA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Acadia Pharmaceuticals posts Q3 loss of $0.53 per share

* Acadia Pharmaceuticals reports third quarter 2017 financial results

BRIEF-Acadia Pharmaceuticals initiates phase III study of Pimavanserin

* Acadia Pharmaceuticals initiates phase III study of Pimavanserin in dementia-related psychosis

Big-name U.S. hedge funds shed healthcare stocks during the rally in second-quarter

Several big-name hedge fund investors trimmed their stakes in healthcare companies in the second quarter as the sector led the broad U.S. stock market higher, rallying amid a Republican effort to repeal and replace President Obama's signature healthcare law.

BRIEF-Acadia pharmaceuticals Q2 loss per share $0.55

* Acadia pharmaceuticals reports second quarter 2017 financial results

BRIEF-ACADIA Pharmaceuticals Q2 loss per share $0.55

* ACADIA Pharmaceuticals Inc - expects that full-year NUPLAZID net sales for 2017 will be between $105 million and $115 million

BRIEF-Acadia Pharmaceuticals Q4 loss per share $0.65

* Acadia Pharmaceuticals reports financial results for the fourth quarter and year ended december 31, 2016

Acadia says Alzheimer's psychosis drug clears mid-stage study

Acadia Pharmaceuticals Inc said on Tuesday its drug to treat psychosis in patients suffering from Alzheimer's disease met its main goal in a mid-stage study, sending its shares up as much as 18.5 percent.

BRIEF-Acadia Pharmaceuticals initiates phase II trial of Pimavanserin

* Acadia Pharmaceuticals initiates phase II trial of Pimavanserin for adjunctive treatment in patients with negative symptoms of schizophrenia Source text for Eikon: Further company coverage:

BRIEF-Acadia Pharmaceuticals initiates phase III trial of pimavanserin for adjunctive treatment in patients with Schizophrenia

* Acadia Pharmaceuticals initiates phase iii trial of pimavanserin for adjunctive treatment in patients with Schizophrenia Source text for Eikon: Further company coverage:

BRIEF-Acadia Pharmaceuticals initiates phase II study of pimavanserin in Alzheimer's disease agitation

* Acadia Pharmaceuticals initiates phase II study of pimavanserin in Alzheimer's disease agitation Source text for Eikon: Further company coverage:

GM to add 650 jobs at Spring Hill factory to meet SUV demand

General Motors said it would add a third shift and 650 jobs at its factory in Spring Hill, Tennessee to meet higher demand for its recently launched Cadillac XT5 and GMC Acadia crossover SUVs.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up